

Please Direct All Correspondence to Customer Number **55389**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Monia et al.
App. No : 10/568,488
Filed : February 14, 2006
For : ANTISENSE MODULATION OF P38
MITOGEN ACTIVATED PROTEIN
KINASE EXPRESSION
Examiner : Unknown
Art Unit : 1635

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 4, 2007
(Date)

Michael L. Fuller, Reg. No. 36,516

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 4 references.
 - (X) Enclosing 3 references.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 55,389
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT

Applicant : Monia, et al.
App. No : 10/568,488
Filed : February 14, 2006
For : ANTISENSE MODULATION OF P38
MITOGEN PROTEIN KINASE
EXPRESSION
Examiner : Unknown
Art Unit : 1635

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 4, 2007
(Date)

Michael L. Fuller, Reg. No. 36,516

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 4 references to be considered by the Examiner. Also enclosed are 3 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 4, 2007

By: Michael L. Fuller

Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 55,389
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/568,488
Filing Date	February 14, 2006
First Named Inventor	Monia, Brett P.
Art Unit	1635
Examiner	Unknown
Attorney Docket No.	ISPH-0859USA / ISIS.029NP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5801154	09-01-1998	Baracchini, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
-------------------	----------	--	--------------------------------	-------------------------------	--	----------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	2	ESCOTT, K.G., et al., "Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat," British Journal of Pharmacology (2000) 131:173-176.	
	3	TAUBE, et al., Inhibition of Early Airway Neutrophilia Does Not Affect Development of Airway Hyperresponsiveness, 2004, American Journal of Respiratory Cell and Molecular Biology, Vol. 30 pgs 837-843.	
	4	UNDERWOOD, et al., SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence, 2000, The Journal of Pharmacology and Experimental Therapeutics, Vol 293, No. 1, pgs 281-288.	

3831803
060107

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.